Evidence map›Paper›PMID 26952014›Full record

ArticleToxicology and applied pharmacology2016

Development and assessment of countermeasure formulations for treatment of lung injury induced by chlorine inhalation.

Gary W Hoyle, Jing Chen, Connie F Schlueter, Yiqun Mo, David M Humphrey, Greg Rawson, Joe A Niño, Kenneth H Carson

Open access · greenAbstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Inhibition of chlorine-induced airway fibrosis by budesonide.Toxicology and applied pharmacology · 2019
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gary W HoyleDepartment of Environmental and Occupational Health Sciences, School of Public Health and Information Sciences, University of Louisville, Louisville, KY, United States. Electronic address: Gary.Hoyle@louisville.edu.
Jing ChenDepartment of Environmental and Occupational Health Sciences, School of Public Health and Information Sciences, University of Louisville, Louisville, KY, United States.
Connie F SchlueterDepartment of Environmental and Occupational Health Sciences, School of Public Health and Information Sciences, University of Louisville, Louisville, KY, United States.
Yiqun MoDepartment of Environmental and Occupational Health Sciences, School of Public Health and Information Sciences, University of Louisville, Louisville, KY, United States.
David M HumphreyDepartment of Environmental and Occupational Health Sciences, School of Public Health and Information Sciences, University of Louisville, Louisville, KY, United States.
Greg RawsonMicroencapsulation and Nanomaterials Department, Chemistry and Chemical Engineering Division, Southwest Research Institute, San Antonio, TX, United States.
Joe A NiñoMicroencapsulation and Nanomaterials Department, Chemistry and Chemical Engineering Division, Southwest Research Institute, San Antonio, TX, United States.
Kenneth H CarsonMicroencapsulation and Nanomaterials Department, Chemistry and Chemical Engineering Division, Southwest Research Institute, San Antonio, TX, United States.
University of Louisville · USSouthwest Research Institute · US

Funding

Novel Therapies for Chlorine-Induced Lung InjuryU01ES015673 · NIEHS · UNIVERSITY OF LOUISVILLE · PI HOYLE, GARY W. · 2006 to 2015
$4.6M
NIEHS NIH HHS U01 ES015673
6 · The paper itself

Abstract

Chlorine is a commonly used, reactive compound to which humans can be exposed via accidental or intentional release resulting in acute lung injury. Formulations of rolipram (a phosphodiesterase inhibitor), triptolide (a natural plant product with anti-inflammatory properties), and budesonide (a corticosteroid), either neat or in conjunction with poly(lactic:glycolic acid) (PLGA), were developed for treatment of chlorine-induced acute lung injury by intramuscular injection. Formulations were produced by spray-drying, which generated generally spherical microparticles that were suitable for intramuscular injection. Multiple parameters were varied to produce formulations with a wide range of in vitro release kinetics. Testing of selected formulations in chlorine-exposed mice demonstrated efficacy against key aspects of acute lung injury. The results show the feasibility of developing microencapsulated formulations that could be used to treat chlorine-induced acute lung injury by intramuscular injection, which represents a preferred route of administration in a mass casualty situation.

Indexed as

Acute Lung InjuryAnimalsBudesonideChemistry, PharmaceuticalChlorineDiterpenesDrug CarriersDrug DiscoveryDrug LiberationEpoxy CompoundsInhalation ExposureInjections, IntramuscularMaleMice, Inbred StrainsMicroscopy, Electron, ScanningPhenanthrenesBudesonideChlorineDiterpenesDrug CarriersEpoxy CompoundsPhenanthrenesRolipramtriptolideAcute lung injuryAirway hyperreactivityMicroencapsulationPulmonary edema

Identifiers

PMID26952014
PMCPMC4821717
OpenAlexW2295923417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.